Update Amyotrophe Lateralsklerose – Diagnostik und Therapie

Bogdan Bjelica; Susanne Petri; Camilla Wohnrade

doi:10.1055/a-2133-1668

Neurologie up2date, Table of Contents

Neurologie up2date 2024; 07(04): 361-377
DOI: 10.1055/a-2133-1668

Bewegungsstörungen

Update Amyotrophe Lateralsklerose – Diagnostik und Therapie

Bogdan Bjelica

,

Susanne Petri

,

Camilla Wohnrade

Abstract

All articles of this category

Amyotrophe Lateralsklerose (ALS) ist die häufigste Motoneuronerkrankung mit Beginn im Erwachsenenalter. Trotz fortschreitender Entschlüsselung der molekularen Pathogenese sind verlaufsmodifizierende Therapieoptionen bei der sporadischen ALS bisher begrenzt, für einige genetische Formen gibt es jedoch äußerst vielversprechende neue Ansätze. Eine multidisziplinäre symptomatische Behandlung kann wesentlich zum Erhalt der Lebensqualität beitragen.

Full Text

References

Literaturverzeichnis
1 Schuchart S. Berühmte Entdecker von Krankheiten: Jean-Martin Charcot begründete die moderne Neurologie. Dtsch Ärztebl Int 2017; 114: 68
2 Goutman SA, Hardiman O, Al-Chalabi A. et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 2022; 21: 480-493
3 Rosenbohm A, Peter RS, Erhardt S. et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 2017; 264: 749-757
4 Logroscino G, Traynor BJ, Hardiman O. et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385-390
5 Al-Chalabi A, Fang F, Hanby MF. et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010; 81: 1324-1326
6 Hardiman O, Al-Chalabi A, Chio A. et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers 2017; 3: 17071
7 Nijs M, Van Damme P. The genetics of amyotrophic lateral sclerosis. Curr Opin Neurol 2024; 37: 560-569
8 Vasta R, Chia R, Traynor BJ. et al. Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine 2022; 75: 103795
9 Bandres-Ciga S, Noyce AJ, Hemani G. et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019; 85: 470-481
10 Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet 2019; 28: 688-697
11 Bradley WG, Borenstein AR, Nelson LM. et al. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases?. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 325-333
12 Li C, Liu J, Lin J. et al. COVID-19 and risk of neurodegenerative disorders: A Mendelian randomization study. Transl Psychiatry 2022; 12: 283
13 Zhang H, Zhou Z. COVID-19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ann Clin Transl Neurol 2022; 9: 1953-1961
14 Sopranzi FM, Faragalli A, Pompili M. et al. Incidence of amyotrophic lateral sclerosis before and during the COVID-19 pandemic: evidence from an 8-year population-based study in Central Italy based on healthcare utilization databases. Amyotroph Lateral Scler Frontotemporal Degener 2024; 25: 554-562
15 Mead RJ, Shan N, Reiser HJ. et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 2023; 22: 185-212
16 Braak H, Brettschneider J, Ludolph AC. et al. Amyotrophic lateral sclerosis – a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708-714
17 Quinn C, Elman L. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Continuum (Minneap Minn) 2020; 26: 1323-1347
18 Meyer T, Dreger M, Grehl T. et al. Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study. Eur J Neurol 2024; 31: e16379
19 Ludolph A, Petri S, Grosskreutz J et al. Motoneuronerkrankungen, S1-Leitlinie, 2021. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed September 21, 2024 at: https://dgn.org/leitlinie/183
20 Joyce NC, Carter GT. Electrodiagnosis in persons with amyotrophic lateral sclerosis. PM R 2013; 5: S89-S95
21 Pugdahl K, Camdessanche JP, Cengiz B. et al. Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clin Neurophysiol 2021; 132: 3183-3189
22 Shen D, Yang X, Wang Y. et al. The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population. Transl Neurodegener 2021; 10: 28
23 Turner MR. UK MND Clinical Studies Group. Diagnosing ALS: the Gold Coast criteria and the role of EMG. Pract Neurol 2022; 22: 176-178
24 Bjelica B, Bartels MB, Hesebeck-Brinckmann J. et al. Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions. J Neurol 2024; 271: 3953-3977
25 Floeter MK, Katipally R, Kim MP. et al. Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders. Neurology 2014; 83: 620-627
26 Desport JC, Preux PM, Truong TC. et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53: 1059-1063
27 Brent JR, Franz CK, Coleman 3rd JM. et al. ALS: Management Problems. Neurol Clin 2020; 38: 565-575
28 Takahashi F, Takei K, Tsuda K. et al. Post-hoc analysis of MCI186–17, the extension study to MCI186–16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 32-39
29 Paganoni S, Macklin EA, Hendrix S. et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 2020; 383: 919-930
30 ClinicalTrials.gov. Ultra-high-caloric, Fatty Diet in ALS (LIPCAL-ALS II). Accessed September 21, 2024 at: https://clinicaltrials.gov/study/NCT06280079
31 Ludolph AC, Dorst J, Dreyhaupt J. et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol 2020; 87: 206-216
32 Miller T, Cudkowicz M, Shaw PJ. et al. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020; 383: 109-119
33 Miller TM, Cudkowicz ME, Genge A. et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022; 387: 1099-1110
34 Boros BD, Schoch KM, Kreple CJ. et al. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics 2022; 19: 1145-1158
35 Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B. et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 2022; 28: 104-116
36 van den Berg LH, Rothstein JD, Shaw PJ. et al. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurol 2024; 23: 901-912
37 Elden AC, Kim HJ, Hart MP. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466: 1069-1075
38 Paganoni S, Berry JD, Quintana M. et al. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Ann Neurol 2022; 91: 165-175
39 Neel DV, Baselga-Garriga C, Benson M. et al. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis. Muscle Nerve 2024; 70: 232-239